Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2013

View Archived Issues

Lexicon Pharmaceuticals reports data on novel SGLT inhibitors for diabetes

The reclassification of endometrial carcinoma subgroup categorization on a genomic basis

Results of phase I expansion study of CC-223 reported

Preclinical data support therapeutic efficacy of UR-1102 for hyperuricemia and gout

Results from first-in-human study of VXM-01 reported

NOX-G16, a new candidate for type 1 diabetes

Roche presents novel agents for HCV infection

Forma Therapeutics and Cancer Research Technology to discover cancer drugs

Omthera Pharmaceuticals submits NDA for Epanova to the FDA

Boehringer Ingelheim discloses novel ACC-beta inhibitors

Lorus Therapeutics reports phase I data for LOR-253

Novel CRTH2 receptor antagonists prepared by Actelion Pharmaceuticals

Bellicum Pharmaceuticals begins trial of novel controlled dendritic cell immunotherapy

Chelsea Therapeutics resubmits Northera NDA

Olema Pharmaceuticals divulges new estrogen receptor modulators

Immunocore and GSK partner to discover ImmTACs against novel targets

Imetelstat shows promise in phase II trial for the treatment of essential thrombocythemia

Acorda Therapeutics acquires two neuropathic pain assets

Sensorion and Griffin receive Eurostars grant to develop new therapies for vestibular disorders

Sorrento and Ben-Gurion University sign agreement to develop anti-HCV antibodies

Calimmune commences phase I/II trial of gene medicine for HIV

Nuvilex to advance cell-encapsulated anticancer drug to phase III trials

Advancell grants Helsinn worldwide license to drug for chemotherapy-induced dermatological injuries

Kinex Pharmaceuticals to lead Orascovery program development in China

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...